Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)

Bayer131 enrolled

Overview

The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with acute deep vein thrombosis treated with Xarelto, in accordance with the terms of the European marketing authorization and the Belgian reimbursement criteria.

Study Type

OBSERVATIONAL

Enrollment

131

Conditions

Venous Thrombosis

Interventions

Rivaroxaban (Xarelto, BAY59-7939)DRUG

Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients with a diagnosis of deep vein thrombosis (DVT) within the past 9 months, enabling at least 3 months of therapy Exclusion Criteria: * Patients who do not fulfil the Belgian reimbursement criteria of deep vein thrombosis (DVT)

Locations (1)

Unnamed facility

Many Locations, Belgium